Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. Oneness Biotech Co's annualized return on capital (ROC %) for the quarter that ended in Dec. 2025 was -13.89%.
As of today (2026-07-17), Oneness Biotech Co's WACC % is -0.93%. Oneness Biotech Co's ROC % is -13.37% (calculated using TTM income statement data).
Oneness Biotech Co earns returns that do not match up to its cost of capital. It will destroy value as it grows.
Oneness Biotech Co (LUX:ONEA) ROC % Explanation
ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.
There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.
Why is ROC % important?
Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.
As of today, Oneness Biotech Co's WACC % is -0.93%. Oneness Biotech Co's ROC % is -13.37% (calculated using TTM income statement data).
Oneness Biotech Co earns returns that do not match up to its cost of capital. It will destroy value as it grows.
Be Aware
Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Oneness Biotech Co ROC % Related Terms
Oneness Biotech Co ROC % Historical Data
* Premium members only.
The historical data trend for Oneness Biotech Co's ROC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note:
The Operating Income data used here is four times the quarterly (Dec. 2025) data.
The tax rate is limited to between 0% and 100%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Oneness Biotech Co (LUX:ONEA) has a ROC % of -13.89% as of Dec. 2025. Return on capital is the ratio of current-period net income to average two-period capital. View historical data on Oneness Biotech Co and its competitors.
Is Oneness Biotech Co's ROC % too high?
Oneness Biotech Co's current ROC % is -13.89%. Overall, Oneness Biotech Co has a GF Score™ of 59/100, reflecting its overall financial health beyond just this single metric.
How does Oneness Biotech Co's ROC % compare to VRTX and REGN?
Oneness Biotech Co's ROC % of -13.89% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC % for a Biotechnology company?
A good ROC % depends on the Biotechnology industry context. However, ROC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC % mean?
A high ROC % can signal that a stock is expensive relative to its fundamentals. Return on capital is the ratio of current-period net income to average two-period capital. View historical data on Oneness Biotech Co and its competitors. Oneness Biotech Co's current ROC % is -13.89%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oneness Biotech Co stock overvalued right now?
Oneness Biotech Co (LUX:ONEA) has a current ROC % of -13.89%. The stock's GF Value™ is $35.65, compared to a current price of $23.60 — trading 33.8% below its estimated fair value. The current ROC % is -13.89%. Oneness Biotech Co's overall GF Score™ is 59/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC % calculated?
ROC % is calculated from a company's financial statements. For Oneness Biotech Co (LUX:ONEA), the current ROC % is -13.89% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Oneness Biotech Co (LUX:ONEA) Overvalued in 2026?
Based on GuruFocus' analysis, Oneness Biotech Co stock appears to be undervalued.
The current stock price of $23.60 is trading 33.8% below its estimated GF Value™ of $35.65.
Key valuation signals for LUX:ONEA:
ROC %: -13.89%
GF Value™: $35.65 vs. price of $23.60 (33.8% below fair value)
No single metric tells the full story. See the LUX:ONEA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Oneness Biotech Co Ltd is engaged in the research and development of new drugs, the sale of pharmaceutical products and health products, and other related businesses. It focuses on developing drugs for the treatment of chronic skin and immune diseases. The Group's product portfolio comprises FESPIXON cream, for the treatment of diabetic foot ulcers, and Bonvadis, a wound care medical device. It also has various other product candidates in its development pipeline, such as FB825, FB704A, SNS812, SNS851, and others. The Group operates in the following reportable segments: New drug research and development, which derives maximum revenue, and the Agricultural products cultivation and organic food segment.
59GF Score
Get the complete analysis for LUX:ONEA
ROC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LUX:ONEA has been successfully added to your 
